Sovremennye printsipy korrektsii metabolicheskogo sindroma u zhenshchin v period postmenopauzy
- Authors: Grigoryan O.R1
-
Affiliations:
- ГУ Эндокринологический научный центр РАМН, Москва
- Issue: Vol 7, No 9 (2005)
- Pages: 734-736
- Section: Articles
- URL: https://ogarev-online.ru/2075-1753/article/view/91979
- ID: 91979
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##References
- Анцифиров М.Б. Ожирение. Метаболический синдром. Сахарный диабет 2 типа. Под ред. академика РАМН И.И.Дедова. М., 2000; с. 53–61.
- Isomaa B, Almgren P, Tuomi T, Forsen B et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabet Care 2001; 24: 683–9.
- Lovejoy J.C. The influence of sex hormones on obesity across the female life span. J Wom Health 1998; 7: 1247–56.
- Manson J.E, Willet W.C, Stampfer M.J et al. Body weight and mortality among women. N Eng J Med 1995; 333: 677–85.
- Milewicz A, Bidzinska B, Sidorowicz A. Perimenopausal obesity. Gynecol Endocrinol 1996; 10: 285–91.
- Ley C.J, Lees B, Stevenson J.C. Sex - and menopause - associated changes in body fat distribution. Am J Clin Nutr 1992; 55: 950–4.
- Pasquali R, Casimirri F, Pascal G et al. Traversing the menopause: changes in energy expenditure and body composition. Coronary Artery Dis 1998; 9: 799–803.
- Poehlman E.T, Tchernof A. Traversing the menopause: changes in energy expenditure and body composition. Coronary Artery Dis 1998; 9: 799–803.
- Carranza L.S, Murillo U.A, Martinez T.N, Santos G.J. Changes in symptoms, blood pressure, glucose, hormones, and lipid levels according to weight and body fat distribution in climacteric women. Int J Fertil 1998; 43: 306–11.
- Bray G.A, Greenway F.L. Current and potential drugs for treatment of obesity. Endocrinol Rev 1999; 20: 805–75.
- Stoak M.J. Sibutramine: “A review of the pharmacology of a novel anti - obesity agent”. Int J Obes Relat Metab Dis 1997; 21: 25–9.
- Сметник В.П., Шестакова И.Г. Эффективность сибутрамина (Меридиа) в лечении ожирения у женщин с менопаузальным метаболическим синдромом. Пробл. репродукции. 2002; 1: 55–7.
- Бутрова С.А. Там же. С. 38–40.
- Giannarelli R, Aragona M, Coppelli A, Del Prato S. Reducing insulin resistance with metformin: the evidence today. Diabet Metabol 2003; 29: 6S28–6S35.
- Бутрова С.А. Эффективность глюкофажа в профилактике сахарного диабета типа 2 (по результатам исследования DPP). Пробл. эндокринол. 2004; 4: 51–6.
- Bouskela E, Cyrino F, Wiernsperger N. Effect of insulin and the combination of insulin plus metformin (glucophage) on microvascular reactivity in control and diabetic hamsters. Angiology 1997; 48: 503–14.
- Chan N. Improved endothelial function with metformin in type 2 diabetes mellitus. JAM Coll Cardiol 2001; 38: 2131–2.
- Charles A, Vague P, Morange P et al. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects. The BIGPROl Study. Diabet Care 1998; 11: 1967–72.
- Despres J. Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. Diabet Metabol 2003; 29: 6S53–61.
- Бутрова С.А. Сибутрамин (Меридиа) в лечении ожирения: опыт применения в России. Клин. фармакол. и тер. 2001; 10 (2): 55–8.
Supplementary files
